Alzheimer disease (AD) is the most common contributor to dementia in the world, but
strategies that slow or prevent its clinical progression have largely remained elusive, until …

Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …

Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …

Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

ApoE is the major lipid and cholesterol carrier in the CNS. There are three major human
polymorphisms, apoE2, apoE3, and apoE4, and the genetic expression of APOE4 is one of …

Microglia are the resident macrophages of the central nervous system (CNS) acting as the
first line of defense in the brain by phagocytosing harmful pathogens and cellular debris …

The key pathological hallmarks—extracellular plaques and intracellular neurofibrillary
tangles (NFT)—described by Alois Alzheimer in his seminal 1907 article are still central to …

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss
and personality changes, eventually leading to dementia. The pathological hallmarks of AD …

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive
memory loss along with neuropsychiatric symptoms and a decline in activities of daily life. Its …

Alzheimer's disease (AD) dementia refers to a particular onset and course of cognitive and
functional decline associated with age together with a particular neuropathology. It was first …